GILD vs NEPH · P/E 18, rev $29.44B vs P/E 48, rev $14.2M
Gilead Sciences Inc (GILD) versus Nephros Inc (NEPH) — a side-by-side from cached financials, not a winner call.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US.
Nephros Inc (NEPH) is a medical instruments & supplies company listed on US.
Latest reported GILD revenue for 2025-12-31 was $29.44B. Net income was $8.51B. Revenue was up 2.4% from 2024-12-31 to 2025-12-31. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Latest reported NEPH revenue for 2024-12-31 was $14.2M. Net income was $74.0K. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. NEPH currently screens at market cap $40.9M and trailing P/E 48.3.
GILD currently screens at market cap $160.15B and trailing P/E 17.5. NEPH currently screens at market cap $40.9M and trailing P/E 48.3.
Not investment advice. Open the GILD and NEPH stock pages for the full models.
Not investment advice.